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Abstract
Aims—Chronic chorioamnionitis is a histological manifestation of maternal anti-fetal cellular
rejection. Failure of graft survival being the most catastrophic event in organ transplantation, we
hypothesized that fetal death could be a consequence of rejection of the mother against the fetus.
This study was conducted to assess evidence of cellular and antibody-mediated rejection in fetal
death cases.
Methods and results—Placental histology was reviewed for the presence of chronic
chorioamnionitis in unexplained preterm fetal death (n=30) and preterm live birth (n=103) cases.
Amniotic fluid CXCL10 concentrations were measured by specific immunoassay. Chronic
chorioamnionitis was more frequent in fetal death cases than in live birth cases (60.0% versus
37.9%; P<0.05) and fetal death cases had a higher median amniotic fluid CXCL10 concentration
than live birth cases (2.0 ng/ml versus 1.8 ng/ml, P<0.05), after adjusting for gestational age at
amniocentesis. Maternal anti-human leucocye antigen (HLA) class II seropositivity determined by
flow cytometry was higher in fetal death cases compared to live birth cases (35.7% versus 10.9%;
P<0.05).
Conclusions—Chronic chorioamnionitis is a common pathology of unexplained preterm fetal
death. The novel findings herein suggest strongly that cellular and antibody-mediated anti-fetal
rejection of the mother is associated with fetal death (graft failure) in human pregnancy.
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Introduction
As more than 3.2 million stillbirths are being reported worldwide every year,1 fetal death is
one of the most challenging and devastating obstetric complications. Meticulous placental
and autopsy examinations are important in the identification of the causes of unexpected
fetal death.2 However, variable fractions of fetal death (ranging from 25% to 60%) cannot
be explained, regardless of clinical and pathological examination, including autopsies.3 Of
note, small-for-gestational-age (SGA) pregnancy is associated frequently with fetal death,4
and evidence suggests strongly that fetal death is associated with a maternal systemic anti-
angiogenic state, which is characterized by decreased plasma concentration of pro-
angiogenic molecules and increased plasma concentration of anti-angiogenic molecules.5,6
We have reported decreased concentration of placental growth factor (PlGF) and elevated
concentrations of anti-angiogenic molecules, such as soluble vascular endothelial growth
factor receptor-1 (sVEGFR-1) and soluble endoglin (sEng), in the maternal circulation at the
time of diagnosis of unexplained fetal death cases.5 A subsequent longitudinal analysis
showed that the pattern of dysregulation of angiogenic and anti-angiogenic factors in fetal
death is distinct from that of pre-eclampsia. Patients destined to develop fetal death have
higher PlGF and lower sVEGFR-1 and sEng plasma concentrations in the first trimester than
do normal pregnancies; this is reversed in the mid- and third trimesters.6 Therefore, it is
highly likely that ongoing, chronic biological perturbations in the feto–maternal
compartments precede this catastrophic event.
Chronic chorioamnionitis is defined as amniotrophic infiltration of maternal T cells into the
chorioamniotic membranes.7,8 It is associated commonly with preterm labour and preterm
prelabour rupture of membranes with increased amniotic fluid (AF) CXCL10 concentration
and CXCL9, CXCL10 and CXCL11 mRNA overexpression in the chorioamniotic
membranes, all of which are T cell chemokines.9 CXCL9, CXCL10 and CXCL11 exert their
effects by binding to CXCR3, which is present in T cells and natural killer cells.10,11
CXCR3 is a G protein-coupled surface receptor, having seven transmembrane α-helical
structures. Its N-terminal extracellular domain is critical for ligand binding while the
intracellular C-terminal domain is involved in signal transduction on receptor activation by
ligand (CXCL9, CXCL10, CXCL11) binding.12 Sharing a common pathogenesis with
villitis of unknown aetiology (VUE), chronic chorioamnionitis is considered a histological
manifestation of maternal anti-fetal cellular rejection occurring in the chorioamniotic
membranes.
The fetus is a semi-allogeneic graft to the mother, and its survival is a key parameter of
successful reproduction. We hypothesized that a subset of fetal death might be analogous to
the failure of graft survival in organ transplantation. Evidence supports that CXCL9,
CXCL10 and CXCL11 are functionally involved in graft rejection. Pre- and post-transplant
CXCL9 and CXCL10 concentrations in patients' sera have predictive value for acute
rejection in cardiac and renal allograft loss.13–16 CXCL11 is a dominant chemokine in
recruiting CXCR3+ T cells into allogeneic skin graft in mice.17 The purpose of this study
was to determine whether the frequency of chronic chorioamnionitis is higher in fetal death
than in a gestational age-matched group of live births.
Materials and methods
Patient Population and Study Materials
All participating patients delivered at Hutzel Women's Hospital, Detroit, Michigan, USA,
and provided written informed consent. The Institutional Review Boards of the participating
institutions approved the collection of clinical information and use of biological materials
for research purposes. We selected cases in which amniotic fluid samples were available
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from the Bank of Biological Materials of the Perinatology Research Branch, Eunice
Kennedy Shriver National Institute of Child Health and Human Development, National
Institutes of Health, Department of Health and Human Services, and abnormalities or major
structural anomalies. Autopsies were performed in all unexplained fetal death cases (n=30),
and major pathology which could explain fetal death was not found. Preterm labour was
defined by the presence of regular uterine contractions with cervical dilation that led to
delivery before 37 weeks of gestation. The SGA cases were defined as less than the 10th
percentile in birth weight for gestational age. Amniotic fluid samples were obtained by
transabdominal amniocentesis from women who underwent amniocentesis for clinical
indications. Samples were kept at −80°C until analysed by immunoassay.
Histopathological Examination
Histopathological assessment of the placental lesions was performed based upon the
diagnostic criteria proposed by the Perinatal Section of the Society for Pediatric
Pathology.18–21 Chronic chorioamnionitis was diagnosed when lymphocytic infiltration into
the chorionic trophoblast layer or chorioamniotic connective tissue was present, as described
previously.9 The extent of inflammation in chronic chorioamnionitis was defined as grade 1
when there were three or more foci of, or patchy, inflammation, and grade 2 when diffuse
inflammation was bserved. 9 The stage of inflammation was evaluated as stage I if
amniotropic lymphocytic infiltration was confined to the chorionic trophoblast layer without
the involvement of the chorioamniotic connective tissue, and stage II if lymphocytic
infiltration into the chorioamniotic connective tissue was noted.9 The haematoxylin and
eosin (H&E) sections of the chorioamniotic membranes roll (n=2), umbilical cord (n=2) and
placental disc (n =3) were examined. Placental findings were reviewed by one pathologist
(C.J.K.), who was masked to all clinical information except for the gestational age at
delivery.
Immunohistochemistry
To confirm that lymphocytic infiltrates into chorioamniotic membranes are T cells,
immunohistochemistry was conducted in representative examples of both live birth cases
(n=5) and fetal death cases (n=5) using 5-μm-thick paraffin sections. Primary antibodies
used were murine monoclonal anti-CD3 (1:50 diluted; Dako, Carpinteria, CA, USA) and
anti-CD8 (1:100 diluted; Dako) and immunostaining was performed using the Ventana
Discovery automatic staining system (Ventana Medical Systems, Tucson, AZ, USA). The
Discovery DAB Map Kit (Ventana Medical Systems) was used to detect the chromogen
reaction.
Enzyme-Linked Immunosorbent Assay (Elisa)
Amniotic fluid samples obtained by transabdominal amniocentesis were centrifuged at 1300
g for 10 min and stored at −80°C until use. The AF concentrations of interleukin (IL-6) and
CXCL10 were measured by specific ELISA (R&D Systems, Minneapolis, MN, USA),
according to the manufacturer's instructions.
Flow Cytometry
Flow cytometric evaluation of panel-reactive anti-HLA class I and class II antibodies in
maternal serum samples was performed using the FlowPRA®-I and FlowPRA®-II
screening tests (One Lambda Inc., Canoga Park, CA, USA), respectively, according to the
manufacturer's instructions. Briefly, 20 μl of serum samples were incubated with
microbeads for 30 min at room temperature with gentle rotation. The beads were washed
three times with 1 ml of FlowPRA wash buffer, and centrifuged at 9000 g for 2 min. The
beads were incubated subsequently with 100 μl of fluorescein isothiocyanate (FITC)-
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conjugated F(ab)2 fragment of Fcγ fragment-specific goat anti-human immunoglobulin
(Ig)G for 30 min. The beads were washed and 0.5 ml of fixing solution [0.5% formaldehyde
in phosphate-buffered saline (PBS)] was added. The FL1 fluorescence of 5000 events was
analysed using BD LSRII flow cytometry (BD Biosciences, San Jose, CA, USA). Samples
with panel reactivity of 10% or more were considered positive for the screening test of
panel-reactive anti-HLA antibodies.22,23
Statistical Analysis
Univariate analysis was performed with an unpaired t-test or a Mann–Whitney U test for
continuous variables and with χ2 tests or Fisher's exact tests for categorical variables, as
appropriate. Analysis of covariance was conducted for comparisons of AF IL-6 and
CXCL10 concentrations among groups to adjust for gestational age at amniocentesis.
Logistic regression analysis was conducted to examine the effect of the placental
histopathological lesions and other clinical variables (e.g. maternal age, drug abuse,
smoking, race, gravida, maternal medical diseases such as hypertensive disorders and
diabetes mellitus, gestational age at delivery, SGA and fetal gender) on the occurrence of
fetal death. Statistical analysis was performed using SPSS version 15.0 (SPSS Inc., Chicago,
IL, USA). A P-value of <0.05 was considered significant.
Results
Frequency Of Chronic Chorioamnionitis
The demographics and clinical characteristics of patients are summarized in Table 1.
Gestational age at amniocentesis, amniocentesis to delivery interval, gravida, parity and the
use of antenatal steroids were among the clinical parameters which showed significant
differences between fetal death and live birth cases. Of note, the percentage of SGA cases
was significantly higher in fetal death (36.7%) than in the live birth group (15.5%) (P<0.05;
Table 1). Representative histological features of chronic chorioamnionitis cases showing
amniotropic T cell infiltration in the chorioamniotic membranes in fetal death cases are
shown in Figure 1. Chronic chorioamnionitis typically showed margination of lymphocytes
in the choriodecidual interface with foci of infiltration into the chorionic trophoblast layer or
chorioamniotic connective tissue. Immunohistochemistry for CD3 and CD8 in
representative live birth (n=5) and fetal death (n=5) cases confirmed that CD8+ cytotoxic T
cells are a major subset of lymphocytic infiltrates. Among the chronic chorioamnionitis
cases (n=57), 63.2% (n=36) of the cases showed focal or patchy lymphocytic infiltrations
compatible with grade 1 inflammation and 36.8% (n=21) of cases had grade 2 inflammation
in the chorioamniotic membranes. In addition, 22.8% (n=13) of cases had stage I
inflammation limited to the chorionic trophoblast layer and 77.2% (n=44) of the cases had
stage II inflammation involving the chorioamniotic connective tissue layer.
Chronic chorioamnionitis was more frequent in fetal death cases than in live birth cases
(60% versus 37.9%, respectively; P<0.05) (Figure 2A). Among cases with chronic
chorioamnionitis, the proportions of grade 2 inflammation and stage II inflammation in fetal
death cases were not different from those in live birth cases (for grade 2 inflammation:
38.9% versus 35.9%; for stage II inflammation: 77.8% versus 76.9%), whereas acute
chorioamnionitis was more frequent in live birth cases than in fetal death cases (43.7%
versus 10.0%, respectively; P=0.001) (Figure 2B). After adjusting for clinical parameters,
including maternal age, drug abuse, smoking, race, gravida, maternal medical diseases such
as hypertensive disorders and diabetes mellitus, gestational age at delivery, SGA and fetal
gender, which could have influenced the occurrence of fetal death in utero, the presence of
chronic chorioamnionitis was an independent risk factor for fetal death [odds ratio
(OR)=2.59, 95% confidence interval (CI) 1.01–6.66, P<0.05]; and the presence of acute
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chorioamnionitis had a protective effect against fetal death in utero (OR=0.09, 95% CI 0.02–
0.40, P=0.001). The frequencies of the placental findings, consistent with maternal vascular
underperfusion (20.4% versus 16.7%) and fetal vascular thrombo-occlusive disease (7.8%
versus 16.7%), were not different between live birth and fetal death cases (Figure 2C,D).
The frequency of VUE in live birth and fetal death cases was similar (8.7% and 10.0%,
respectively).
Amniotic Fluid IL-6 and Cxcl10 Concentrations
Amniotic fluid samples in all cases of live birth (n=103) and fetal death (n=30) were assayed
for IL-6 and CXCL10. AF IL-6 concentration was not different between live birth (median:
3.0 ng/ml, range: 0.1–1,101.0 ng/ml) and fetal death (median: 2.4 ng/ml, range: 0.3–36.1 ng/
ml), after adjusting for gestational age at amniocentesis (Figure 3A). When the cases were
compared according to the presence or absence of acute and chronic chorioamnionitis, the
presence of acute chorioamnionitis was associated with an elevated AF IL-6 concentration
after adjusting for gestational age at amniocentesis (Figure 3B). The median AF IL-6
concentration was significantly higher in cases with isolated acute chorioamnionitis (n=29)
(median: 17.6 ng/ml, range: 0.3–1–101.0 ng/ml) than in those without chorioamnionitis
(n=47) (median: 1.4 ng/ml, range: 0.2–36.1 ng/ml) and in those with isolated chronic
chorioamnionitis (n=38) (median: 1.4 ng/ml, range: 0.1–30.6 ng/ml) (P<0.05, for each). The
median AF IL-6 concentration was also higher in cases with concomitant acute and chronic
chorioamnionitis (n=19) (median: 23.9 ng/ml, range: 0.1–360.1 ng/ml) than in those without
chorioamnionitis and in those with isolated chronic chorioamnionitis (P<0.01, for each),
whereas a higher AF CXCL10 concentration was observed in fetal death (median: 2.0 ng/ml,
range: 0.1–26.3 ng/ml) than in live birth (median: 1.8 ng/ml, range: 0.0–20.8 ng/ml), after
adjusting for gestational age at amniocentesis (P<0.01; Figure 3C). As is the case with acute
chorioamnionitis, chronic chorioamnionitis was associated with the elevation of AF
CXCL10 concentration, after adjusting for gestational age at amniocentesis (Figure 3D).
Cases with isolated chronic chorioamnionitis had a higher median AF CXCL10
concentration (median: 3.0 ng/ml, range: 0.2–23.3 ng/ml) than those without
chorioamnionitis (median: 1.3 ng/ml, range: 0.1–7.1 ng/ml) and those with isolated acute
chorioamnionitis (median: 2.3 ng/ml, range: 0.2–12.4 ng/ml) (P<0.05, for each). AF
CXCL10 concentrations in chronic chorioamnionitis cases with grade 1 inflammation
(median: 2.9 ng/ml, range: 0.0–15.7 ng/ml) and grade 2 inflammation (median: 3.3 ng/ml,
range: 0.8–26.3 ng/ml) were higher than in cases without chronic chorioamnionitis (median:
1.5 ng/ml, range: 0.1–12.4 ng/ml) (P<0.01, for each). Similarly, chronic chorioamnionitis
cases with stage I inflammation (median: 5.3 ng/ml, range: 1.0–15.7 ng/ml) and stage II
inflammation (median, 2.8 ng/ml: range, 0.0–26.3 ng/ml) had higher median AF CXCL10
concentrations than cases without chronic chorioamnionitis (P<0.01, for each). Cases with
concomitant acute and chronic chorioamnionitis (median: 3.3 ng/ml, range: 0.0–13.2 ng/ml)
also had a significantly higher median of AF CXCL10 concentration than those without
chorioamnionitis (P<0.01).
Panel-Reactive Anti-Hla Antibodies In Maternal Sera
Given that chronic chorioamnionitis displays pathological features of cellular rejection, and
that both cellular and humoral antibody-mediated rejection mechanisms are important in the
development of allograft rejection, we screened for the presence of panel-reactive anti-HLA
class I and class II antibodies in maternal circulation. Flow cytometric analysis was
performed in maternal serum samples obtained at the time of delivery in preterm live birth
cases (n=57) and preterm fetal death cases (n=18). Flow cytometry demonstrated clearly that
some patients have panel-reactive anti-HLA antibodies in their circulation. Maternal
seropositivity for anti-HLA class I antibodies was not different between preterm live birth
and fetal death cases (30.9% versus 35.7%, respectively; Figure 4A). However, the
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seropositivity for anti-HLA class II antibodies was significantly different between preterm
live birth and fetal death cases (10.9% versus 35.7%; P<0.05; Figure 4B).
Discussion
Fetal death could be associated with several maternal and feto–placental conditions such as
infection, alloimmunization and congenital anomalies.24,25 Korteweg et al., using the Dutch
Tulip cause of death classification for perinatal mortality, proposed that the main causes of
fetal death are placental disorders (64.9%), congenital anomalies (5.3%), infection (1.9%),
other (4.8%) and unknown (23.1%).26,27 The primary finding of our study is that chronic
chorioamnionitis is a major placental lesion of preterm fetal death, which might explain a
major subset of unexplained fetal death cases. We also demonstrate, for the first time, that
panel-reactive anti-HLA class II antibodies, which are evidence of anti-fetal antibody-
mediated rejection, are found more frequently in maternal sera of fetal death than in live
birth cases.
Immunohistological findings observed in the present study confirmed that chronic
chorioamnionitis is CD8+ cytotoxic T cell-rich inflammation. While the severity (grade and
stage of inflammation) of chronic chorioamnionitis was not different between cases of live
birth and fetal death, we have also found that amniotic fluid CXCL10 concentration is
higher even in grade 1 or stage I inflammation. This is consistent with the findings in our
previous analysis of chronic chorioamnionitis in various obstetric settings, in that even
histologically mild cases have a robust elevation of amniotic fluid CXCL10 concentration.9
Therefore, meticulous histological evaluation to detect low-grade, low-stage chronic
chorioamnionitis would be important.
In addition to T cell chemokine activity, interferon (IFN)-γ-inducible CXCL9, CXCL10 and
CXCL11 share anti-angiogenic properties on CXCR3+ vascular endothelial cells.28,29
CXCL10 antagonizes the actions of VEGF on tube formation in Matrigel™, and also cell
motility of CXCR3+ endothelial cells.30 It also induces regression of newly formed vessels
via activation of CXCR3 on endothelial cells.31 An intriguing observation in this study is
that the proportion of SGA cases is significantly greater in fetal death, while the frequency
of placental lesions consistent with maternal vascular underperfusion or fetal vascular
thrombo-occlusive disease was not different between fetal death and live birth cases. This
implies that the mechanism of SGA in fetal death cases cannot be attributed solely to
placental underperfusion. Villitis of unknown aetiology is the villous counterpart of chronic
chorioamnionitis characterized by maternal T cell infiltration into fetal chorionic villi, and
we have demonstrated systemic elevation of CXCL9, CXCL10 and CXCL11 in both
maternal and umbilical cord plasma in cases with VUE.32,33 Villitis of unknown aetiology
can accompany obliterative fetal vasculopathy of the placental villous tree and SGA
showing potential impact of increased anti-angiogenic chemokines.34,35 Previous studies
also have shown lower birth weight percentile and fetal growth restriction as features of
cases with chronic chorioamnionitis.7,8 In this context, the systemic anti-angiogenic milieu
in the fetus could explain the development of SGA in some fetal deaths, although its causal
relationship and pathobiology require further studies.
Panel-reactive anti-HLA antibodies (anti-paternal/fetal antibodies) have been studied mainly
in the settings of recurrent spontaneous abortions and miscarriages.36–38 In this study, we
found for the first time that anti-HLA antibodies were detected more frequently in maternal
circulation of fetal death than in live birth cases. In addition to chronic chorioamnionitis, this
is strong evidence for the presence of maternal anti-fetal rejection, which could be a
fundamental derangement associated with or causally related to fetal death. In this context,
the clinicopathological findings described meticulously in the original study of chronic
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chorioamnionitis is significant and has profound implications. Gersell et al. reported that
seven of 17 patients with chronic chorioamnionitis had a history of spontaneous abortion,
fetal death or preterm birth.7 These three conditions could actually be different
manifestations of a common pathophysiology: maternal anti-fetal rejection. The fetus is
protected from maternal immune responses by trophoblasts which mainly express fewer
polymorphic HLA-G molecules.39,40 Maternal sensitization to HLA antigens can result from
previous pregnancy, transfusion, feto–maternal haemorrhage and potential fetal cell
trafficking into the mother.41–43 The significant difference in seropositivity of anti-HLA
class II but not anti-HLA class I antibodies between fetal death and live birth groups is
intriguing, because HLA class II antigens are not expressed in the cells at the very site of the
feto–maternal interface, the trophoblasts. However, anti-HLA antibodies which cross the
placenta are found in fetal circulation,44 and neonatal thrombocytopenia by maternal anti-
HLA antibodies has been reported as a side effect following allogenic leucocyte
immunization in women with recurrent abortions.45 Therefore, further investigation is
required to determine whether maternal anti-HLA antibodies induce distinct types of fetal
damage in addition to known alloimmune reactions such as red-cell alloimmunization and
alloimmune thrombocytopenia.46,47
Several previous studies in humans and mice have indicated that the activation of the
complement system leads to preterm birth, pre-eclampsia and fetal death.48 Concentrations
of C5a and fragment Bb, arkers of the activation of the alternative pathway of the
complement system, are elevated in women with preterm labour.48,49 More importantly, in a
murine model of peri-implantation pregnancy loss and intrauterine growth restriction,
Girardi et al. have shown that C5a generated by the activation of the alternative pathway of
the complement system is an essential trigger of fetal injury, and that complement activation
products induce increased release of sVEGFR-1 from mouse splenic macrophages.50 These
findings are consistent with the changes in maternal plasma pro- and anti-angiogenic factors,
including elevation of sVEGFR-1. In conjunction with this observation in mice, it has been
demonstrated that the median plasma concentration of C5a is higher in patients with fetal
death than in normal pregnant women.51 Therefore, it is also possible that activation of the
classical pathway of the complement system by complement-fixing anti-HLA antibodies
functions as a link between an anti-angiogenic state and fetal death.
A limitation of this study is the definition of unexplained fetal death. Fetal death is
considered unexplained when a cause cannot be identified by fetal, maternal, placental and
obstetric factors.3 Bonetti et al. have reported that scrupulous clinicopathological analyses,
including fetal autopsies and placental examinations, could explain more than 80% of fetal
death cases.2 However, establishment of causality with placental lesions in fetal death is
difficult unless there are unequivocal findings such as rupture of vasa previa and abruption.
Similarly, in their recent proposal the Stillbirth Collaborative Research Network also
excluded isolated acute histological chorioamnionitis and SGA from direct causes of death
and listed only extensive and severe placental changes among possible and probable causes
of fetal death.52 The placental lesions such as acute chorioamnionitis and maternal vascular
underperfusion are actually far more common in live births.6 In the present study, we
defined clinically unexplained fetal death as fetal death without definite causes such as
placental abruption, torsion and/or stricture of umbilical cord sufficient to cause fetal death,
and fetal chromosomal abnormalities or major structural anomalies. Another issue in the
interpretation of the results of this study is the significant difference in the amniocentesis-to-
delivery interval between fetal death cases (study group) and live birth cases (control group).
This seems to be an unavoidable problem due to a difference in clinical presentation. All
maternal serum samples were also obtained only at the time of delivery; thus, the role of
changing dynamics of maternal anti-HLA antibodies across gestation could not be
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determined. Therefore, further observations on a longitudinal basis would be necessary in
the future.
Collectively, the findings of the present study suggest strongly that a substantial proportion
of preterm fetal deaths has a biological signature of maternal anti-fetal rejection. Chronic
chorioamnionitis is a major placental lesion in clinically unexplained preterm fetal death.
Identification of the deleterious effects of anti-angiogenic T cell chemokines (CXCL9,
CXCL10, CXCL11) in maternal, fetal and placental compartments would be a key to
understanding the pathogenesis of unexplained preterm fetal death. Assessment of potential
immunopathological consequences associated with alloimmune anti-HLA antibodies will be
another important area for future research, and a recent observation by Nielsen et al., that the
presence of these antibodies in early pregnancy is associated with a reduced likelihood of a
live birth, could be an important piece of supportive evidence for the proposal described
herein.38
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sEng soluble endoglin
sVEGFR-1 soluble vascular endothelial growth factor receptor-1
VUE villitis of unknown aetiology
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Figure 1.
Immunohistological features of chronic chorioamnionitis in preterm live birth and fetal
death cases. T cell infiltrates are largely composed of CD8+ T cells. A, A preterm live birth
case showing infiltration of CD8+ T cells into the chorionic trophoblast layer. B, A preterm
live birth case with destruction and thinning of chorionic trophoblast layer by infiltrating
CD8+ T cells. C, Infiltration of CD8+ T cells into the chorionic connective tissue layer in a
case of fetal death. D, A fetal death case shows margination of CD8+ T cells at the
choriodecidual interface with foci of scattered lymphocytic infiltration into the chorionic
trophoblast layer.
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Figure 2.
Comparisons of frequencies of placental lesions between preterm live birth cases and
preterm fetal death cases. Chronic chorioamnionitis is more frequent in fetal death cases (A,
P<0.05), while acute chorioamnionitis is more frequent in live birth cases (B, P =0.001).
Conversely, no difference was noted in the findings consistent with maternal vascular
underperfusion (C) and fetal vascular thrombo-occlusive disease (D). CCA: chronic
chorioamnionitis; ACA: acute chorioamnionitis; MVU: maternal vascular underperfusion;
FVTOD: fetal vascular thrombo-occlusive disease; NS: not significant.
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Figure 3.
Amniotic fluid (AF) concentrations of interleukin (IL)-6 and CXCL10 in live birth and fetal
death cases and in acute and chronic chorioamnionitis cases. A, AF IL-6 concentration is not
different between cases with live birth and fetal death. B, The presence of acute
chorioamnionitis, regardless of chronic chorioamnionitis, is associated with a robust
increase in IL-6. C, Fetal death cases have a higher median AF CXCL10 concentration than
live birth cases (P<0.05). D, Median AF CXCL10 concentrations are elevated in cases with
isolated chronic chorioamnionitis and cases with concomitant acute and chronic
chorioamnionitis, compared to cases without chorioamnionitis (P<0.05, for each). All
comparisons of AF IL-6 and CXCL10 concentrations are performed after adjusting for
gestational age at amniocentesis. *P<0.05; **P<0.01; ***P<0.001. AF: amniotic fluid;
CCA: chronic chorioamnionitis; ACA: acute chorioamnionitis.
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Figure 4.
Panel-reactive anti-human leucocyte antigen (HLA) antibodies in maternal sera. A, Flow
cytometric analysis clearly shows anti-HLA class I (left) and anti-HLA-class II (right)
antibodies in maternal sera of a fetal death case. B, Seropositivity for anti-HLA class II but
not anti-HLA class I antibodies is significantly higher in mothers with fetal death compared
to those who gave preterm live births (P<0.05). NS: not significant.
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Table 1
Demographic and clinical characteristics of study population
Preterm Live birth n=103 preterm Fetal death n=30 P- value
Maternal age (years)* 23 (16–44) 25.5 (16–35) NS
Primigravida (%) 23.3 (24/103) 43.3 (13/30) 0.031
Nullipara (%) 36.9 (38/103) 56.7 (7/30) 0.053
Gestational age at delivery (weeks)* 31.9 (20.4–36.4) 31.0 (21.6–36.9) NS
Birth weight (g)* 1588 (280–2920) 1431.5 (304–3400) NS
Small for gestational age (%) 15.5 (16/103) 36.7 (11/30) 0.011
Baby gender (male) (%) 53.4 (55/103) 56.7 (17/30) NS
Antenatal steroid use (%) 83.5 (86/103) 0.0 (0/30) <0.001
Caesarean delivery (%) 35.9 (39/103) 0.0 (0/30) <0.001
Hypertensive disorders in pregnancy (%) 6.8 (7/103) 3.3 (1/30) NS
Diabetes mellitus (%) 1.9 (2/103) 3.3 (1/30) NS
Smoking (%) 25.2 (26/103) 23.3 (7/30) NS
Drug abuse (%) 19.4 (20/103) 20.0 (6/30) NS
Gestational age at amniocentesis (weeks)* 28.6 (15.4–35.9) 30.9 (21.6–36.9) 0.046
Amniocentesis to delivery interval (days)* 6.0 (0–89) 0.7 (0–3) <0.001
*
Median (range).
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